IO’s Impact On Strategic Decision-Making In The Broader Oncology Landscape
Market signals from the pioneering immuno-oncology therapies suggest a paradigm shift across multiple oncology indications in the coming years. To ensure that non-IO products become successful components of the standard of care in cancer, drug developers must consider how IO may impact clinical development, market access and commercialization strategies.
You may also be interested in...
Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.
Nearly half of all late-stage cancer trials that started in 2015 had an antibody component, and 2016 brings the first full survival data from pivotal multi-checkpoint antibody trials. We document the immuno-oncology surge in data.
Big Pharma and Mid Pharma companies have signed over 200 immuno-oncology deals in the last five years, creating the most lucrative class in dealmaking, according to a recent Datamonitor Healthcare report. Bristol-Myers Squibb and Merck & Co. have led the charge, and the PD-L1/PD-1 target still dominates.